Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-D4) – HRP

SARS-CoV-2 Nucleocapsid (N) Protein

This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. <b> (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)</b>

This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.

Ships Overnight on Blue Ice

Anti-SARS-CoV-2 Nucleocapsid, clone NP1-D4, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Furthermore, it is reported to bind to the RNA binding domain of the N protein.

Coronavirus disease 2019 (COVID-19) is caused by the Coronaviridae family virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)¹. SARS-CoV-2 has four structural proteins encoded by its single-stranded, positive-sense RNA genome: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins². The N protein is a highly conserved 46 kDa protein that shares 90% homology with SARS-CoV³. The N protein has an N-terminal (NTD) and C-terminal domain (CTD), which bind to RNA and self-oligomerize, respectively^4,5, forming a helical nucleocapsid structure within the viral envelope⁶. Other functions of the N protein included viral transcription, replication, and modulating cell signaling pathways^7,8. The N protein is abundantly expressed during infection, and antibodies^3,9 and memory T cells^10,11 targeting the N protein have been identified in convalescent sera. Therefore, the N protein is a target in some vaccines and diagnostic assays¹². The N protein also has therapeutic potential, as it evades RNAi-mediated antiviral responses¹³.

The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.
3. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
4. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
5. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
6. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
7. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
8. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
9. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
10. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020.
11. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.
12. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.